SCHEMBL10205140

SCHEMBL10205140

CNC1(C(=O)N2CCC(c3ccc(Nc4ncc(Cl)c(NCc5cccc6c5C(C)(C)C(=O)N6)n4)c(C)c3)CC2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 3/20 0.43
▸ EGFR P00533 5/20 0.41
▸ FLT4 P35916 1/20 0.39
▸ PTK2 Q05397 1/20 0.39
▸ IGF1R P08069 3/20 0.39
▸ NTRK1 P04629 3/20 0.39
▸ NTRK3 Q16288 1/20 0.39
▸ NTRK2 Q16620 1/20 0.39
▸ ALK Q9UM73 3/20 0.37
▸ INSR P06213 1/20 0.37
▸ AXL P30530 1/20 0.37
▸ JAK3 P52333 2/20 0.37
▸ KCNH2 Q12809 1/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ JAK1 P23458 1/20 0.36
▸ TTK P33981 1/20 0.36
▸ FLT3 P36888 1/20 0.36
▸ TXK P42681 1/20 0.36
▸ BLK P51451 1/20 0.36
▸ BTK Q06187 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10205153 0.91 LRRK2 (0.44) LRRK2EGFRFLT4PTK2IGF1R
SCHEMBL10207045 0.90 ALK (0.47) LRRK2EGFRFLT4PTK2IGF1R
SCHEMBL10207048 0.90 FLT4 (0.44) FLT4NTRK1NTRK3NTRK2AXL
SCHEMBL10205148 0.89 LRRK2 (0.43) LRRK2EGFRFLT4PTK2IGF1R
SCHEMBL10205144 0.89 ALK (0.46) LRRK2EGFRFLT4PTK2IGF1R
SCHEMBL10207047 0.89 LRRK2 (0.42) LRRK2EGFRFLT4PTK2IGF1R
SCHEMBL10205534 0.89 ALK (0.46) LRRK2EGFRFLT4PTK2IGF1R
SCHEMBL10205209 0.88 ALK (0.47) EGFRFLT4PTK2IGF1RNTRK1
SCHEMBL10205151 0.88 EGFR (0.44) LRRK2EGFRIGF1RALKINSR
SCHEMBL16255604 0.88 FLT4 (0.41) LRRK2EGFRFLT4PTK2IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655358-B1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2014-11-19 — — EP disclosed
US-8546443-B2 Benzylic oxindole pyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 — — US disclosed
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-27 — — US disclosed
WO-2012085126-A1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES MKI67, CCNI, CCNB1 LRRK2 677/4885EGFR 1397/4885FLT4 2572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback